News from oasmia pharmaceutical ab A wide array of domestic and global news stories; news topics include politics/government, business, technology, religion, sports/entertainment, science/nature, and health/lifestyle. Articles that appear in this section may be written in English or other languages.

Latest

Apr 27, 2016, 10:00 ET Oasmia Pharmaceutical verkündet positive allgemeine Überlebensergebnisse von der Phase-III-Studie mit Apealea/Paclical für die Behandlung von Eierstockkrebs

Die Daten zur Gesamtüberlebensrate aus der Phase-III-Studie erreichen den primären Endpunkt und belegen, dass die Bevorzugung von...


Apr 27, 2016, 07:00 ET Oasmia Pharmaceutical Announces Positive Overall Survival Results From Phase III Study of Apealea/Paclical for Treatment of Ovarian Cancer

Oasmia Pharmaceutical AB (NASDAQ: OASM), a developer of a new generation of drugs within human and veterinary oncology, today announced positive...


Apr 27, 2016, 02:30 ET Oasmia presenterar positiva överlevnadsdata från fas III-studie med Apealea/Paclical för behandling av äggstockscancer

Överlevnadsdata (Overall Survival data) från fas III-studien visade att studiemålet om non-inferiority gällande...


Feb 08, 2016, 14:11 ET Oasmia a déposé une demande d'autorisation de mise sur le marché de son produit phare contre le cancer, Apealea® (Paclical®), auprès de l'Agence européenne des médicaments

Oasmia Pharmaceutical AB (NASDAQ : OASM), a annoncé aujourd'hui avoir déposé une demande d'autorisation de mise sur le...


Feb 08, 2016, 12:12 ET Oasmia presenta una solicitud de autorización de marketing para Apealea®

- Oasmia presenta una solicitud de autorización de marketing a la Agencia Europea del Medicamento para su producto contra el cáncer...


Feb 08, 2016, 11:29 ET Oasmia presenta solicitud de autorización de comercialización ante la Agencia Europea de Medicamentos para su producto líder para el cáncer Apealea® (Paclical®)

Oasmia Pharmaceutical AB (NASDAQ:OASM) anunció hoy la presentación de una solicitud de autorización de comercialización ante la...


Feb 08, 2016, 11:28 ET Oasmia beantragt Marktzulassung seines führenden Krebsproduktes Apealea® (Paclical®) bei der Europäischen Arzneimittel-Agentur

Oasmia Pharmaceutical AB (NASDAQ: OASM) gab heute bekannt, bei der Europäischen Arzneimittel-Agentur (EMA) einen Antrag auf...


Feb 08, 2016, 09:26 ET Oasmia apresentou um pedido de autorização de marketing à Agência Europeia de Medicamentos para seu produto contra o câncer Apealea® (Paclical®)

Oasmia Pharmaceutical AB (NASDAQ:OASM) anunciou hoje a apresentação de um pedido de autorização para marketing (MAA) para a...


Feb 08, 2016, 07:00 ET Oasmia Has Submitted a Marketing Authorization Application to the European Medicines Agency for Its Lead Cancer Product Apealea® (Paclical®)

Apealea is a novel formulation of paclitaxel based on the patented excipient platform XR-17, which forms micellar nanoparticles with paclitaxel....


Feb 08, 2016, 02:50 ET Oasmias har ansökt om marknadsföringstillstånd hos den Europeiska läkemedelsmyndigheten (EMA) för cancerläkemedlet Apealea® (Paclical®)

Oasmia Pharmaceutical AB (NASDAQ: OASM) meddelar idag att en ansökan om marknadsföringstillstånd har skickats till den Europeiska...


Nov 05, 2015, 07:00 ET Oasmia Pharmaceutical AB Confirms Final Data Indicating Positive Top-line Results for Paclical® From Head-to-Head Comparison Study with Abraxane®

- Final analysis of the pharmacokinetic study confirms that water soluble and solvent free Paclical and US-market approved Abraxane have nearly...


Oct 30, 2015, 07:00 ET Oasmia Pharmaceutical Receives Order of $7.5 Million in End-user Value for the Russian Market

Oasmia Pharmaceutical AB (NASDAQ: OASM, FWB: OMAX) - a developer of a new generation of drugs within human and veterinary oncology, announced...


Aug 04, 2015, 07:26 ET Oasmia Pharmaceutical gibt positive Topline-Ergebnisse für Paclical® aus Kopf-an-Kopf-Vergleichsstudie mit Abraxane® bekannt

Vorläufige Studienergebnisse zeigen, dass das wasserlösliche und lösungsmittelfreie Paclical® sowie das auf dem US-Markt...


Aug 04, 2015, 07:00 ET Oasmia Pharmaceutical Announces Positive Top-line Results for Paclical® From Head-to-Head Comparison Study with Abraxane®

Preliminary study findings show that water soluble and solvent free Paclical®, and US-market...


Aug 04, 2015, 05:25 ET Oasmia Pharmaceutical anuncia resultados positivos de primera línea de Paclical® en su estudio comparativo con Abraxane®

Los descubrimientos preliminares del estudio muestran que Paclical®, soluble en agua y libre de solventes, y Abraxane®, con...


Aug 04, 2015, 03:00 ET Oasmia Pharmaceutical annonce des résultats initiaux positifs pour Paclical® dans le cadre d'une étude de comparaison directe avec Abraxane®

Les résultats préliminaires de l'étude montrent que Paclical®, produit soluble dans l'eau et sans solvant, et Abraxane®,...


Aug 04, 2015, 02:15 ET Oasmia Pharmaceutical anuncia resultados preliminares positivos para Paclical® en estudio comparativo directo con Abraxane®

Los hallazgos preliminares del estudio muestran que Paclical®, soluble en agua y libre de solventes, y Abraxane®, aprobado...


Aug 04, 2015, 02:15 ET Oasmia Pharmaceutical anuncia resultados finais positivos para Paclical® em estudos comparativos com Abraxane®

Descobertas em estudos preliminares mostram que Paclical®, solúvel em água e sem solventes, e Abraxane®, remédio aprovado...


Jul 07, 2015, 07:00 ET Oasmia Pharmaceutical Files a Registration Statement on Form F-1/A for its Proposed Public Offering and an Application with NASDAQ for a US Listing and Announces Investor Roadshow

Oasmia Pharmaceutical AB, a developer of a new generation of drugs within human and veterinary oncology, has filed a registration statement on...


Jul 07, 2015, 07:00 ET Oasmia Pharmaceutical Launches US Brand and Sales Platform

Oasmia Pharmaceutical AB, a developer of a new generation of drugs within human and veterinary oncology, today announced that it has established...


Apr 20, 2015, 16:04 ET Paclical®, le produit phare de traitement du cancer d'Oasmia, reçoit l'approbation de commercialisation dans la Fédération de Russie

Oasmia Pharmaceutical AB (« Oasmia ») a annoncé aujourd'hui que Paclical, son produit phare de traitement du cancer, a...


Apr 20, 2015, 16:03 ET Oasmias führendes Krebsprodukt Paclical® erhält Marktzulassung in der Russischen Föderation

Oasmia Pharmaceutical AB ("Oasmia") gab heute bekannt, dass sein führendes Krebsprodukt Paclical vom russischen Gesundheitsministerium die...


Apr 20, 2015, 10:00 ET Oasmia's Lead Cancer Product Paclical® Receives Market Approval in the Russian Federation

Oasmia Pharmaceutical AB ("Oasmia") announced today that its lead cancer product Paclical received market authorization in the Russian Federation...


Dec 03, 2013, 03:48 ET FDA godkänner Oasmias produktionsanläggning i Uppsala

Läkemedelsbolaget Oasmia Pharmaceutical AB (publ) tillkännager idag att bolagets tillverkningsenhet i Uppsala med tillfredställande...


Dec 03, 2013, 02:45 ET Oasmia meddelar att bolagets tillverkningsenhet i Uppsala har framgångsrikt genomgått FDA-inspektion

Läkemedelsbolaget Oasmia Pharmaceutical AB (publ) tillkännager idag att bolagets tillverkningsenhet i Uppsala med tillfredställande...